Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) EBITDA Margin (2016 - 2017)

Historic EBITDA Margin for Soleno Therapeutics (SLNO) over the last 5 years, with Q2 2017 value amounting to 296800.0%.

  • Soleno Therapeutics' EBITDA Margin fell 1820500000.0% to 296800.0% in Q2 2017 from the same period last year, while for Dec 2017 it was 4575.56%, marking a year-over-year decrease of 35999300.0%. This contributed to the annual value of 75969.26% for FY2024, which is N/A changed from last year.
  • Latest data reveals that Soleno Therapeutics reported EBITDA Margin of 296800.0% as of Q2 2017, which was down 1820500000.0% from 518.11% recorded in Q1 2017.
  • Soleno Therapeutics' EBITDA Margin's 5-year high stood at 195.07% during Q2 2014, with a 5-year trough of 296800.0% in Q2 2017.
  • For the 5-year period, Soleno Therapeutics' EBITDA Margin averaged around 28691.43%, with its median value being 645.95% (2016).
  • Per our database at Business Quant, Soleno Therapeutics' EBITDA Margin surged by 100735800bps in 2016 and then tumbled by -1820500000bps in 2017.
  • Soleno Therapeutics' EBITDA Margin (Quarter) stood at 173.91% in 2013, then tumbled by -54bps to 79.54% in 2014, then crashed by -1926bps to 1452.24% in 2015, then skyrocketed by 56bps to 645.95% in 2016, then crashed by -45848bps to 296800.0% in 2017.
  • Its EBITDA Margin was 296800.0% in Q2 2017, compared to 518.11% in Q1 2017 and 645.95% in Q4 2016.